Brought to you by 
Novartis pays up to $5.3bn to acquire Takeda's Xiidra for dry eye
10 May 2019
Executive Summary
Further boosting its ophthalmic pharmaceuticals portfolio, Novartis AG agreed to acquire Takeda Pharmaceutical Co. Ltd.'s dry eye drug Xiidra (lifitegrast) 5% topical solution and all assets associated with it.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com